First beta testing agreement for Biopixlar with Cellectricon
Fluicell AB today announces that the company has entered into an agreement with Cellectricon AB for beta testing of the Biopixlar® high-precision bioprinting platform.
The purpose of the beta test is to get external client and user feedback before taking Biopixlar® into full-scale commercial production. Cellectricon will also assist in application development within their core expertise area of drug discovery for central nervous system (CNS) disorders, and chronic pain. Biopixlar® is planned to be released to the market in 2019.
Fluicell CEO Victoire Viannay comments
“We are extremely pleased to be able to ship our first Biopixlar beta prototype for testing. It has been an intense period of product development and we are curious and excited to hear Cellectricon’s feedback. We know that the instrument is in very good hands and we have been working with Cellectricon for many years, and we truly appreciate the collaboration. We are currently preparing the market launch of Biopixlar® and beta testing is one of the final steps before launch. The objective for the collaboration with Cellectricon is also to identify additional applications for Biopixlar®.”
Cellectricon CEO Mattias Karlsson comments
“We see great potential in Fluicell’s Biopixlar unique and proprietary bioprinting technology. The capability of this exciting technology to enable precise control of the cellular composition and spatial distribution within a cell culture has the potential to open up completely new avenues for in vitro modelling of a wide range of central and peripheral nervous system related diseases. We are looking forward towards evaluating the Biopixlar technology to learn more about it’s potential for creating in vitro models of chronic pain and CNS diseases for applications in the early drug discovery process.”